Gentium SpA Stock Rating Reaffirmed by Brean Capital (GENT)
Gentium SpA (NASDAQ:GENT)‘s stock had its “buy” rating reiterated by Brean Capital in a research note issued on Tuesday, StockRatingsNetwork reports.
Several other analysts have also recently commented on the stock. Analysts at Zacks upgraded shares of Gentium SpA from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, October 16th. They now have a $30.50 price target on the stock. Finally, analysts at Wedbush raised their price target on shares of Gentium SpA from $20.00 to $35.00 in a research note to investors on Monday, September 30th. They now have an “outperform” rating on the stock.
Gentium SpA (NASDAQ:GENT) traded up 6.62% on Tuesday, hitting $31.548. The stock had a trading volume of 330,869 shares. Gentium SpA has a 52-week low of $6.96 and a 52-week high of $30.20. The stock has a 50-day moving average of $24.49 and a 200-day moving average of $14.03. The company has a market cap of $478.7 million and a P/E ratio of 101.34.
Gentium SpA (NASDAQ:GENT) last issued its quarterly earnings data on Tuesday, August 13th. The company reported $0.16 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.02 by $0.14. Analysts expect that Gentium SpA will post $0.45 EPS for the current fiscal year.
Gentium S.p.A. is a biopharmaceutical company focused on the development and manufacture of defibrotide, a drug based on single-stranded deoxyribonucleic acid (NASDAQ:GENT) derived from pig intestines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.